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Recombinant Incretin-Secreting 
Microbe Improves Metabolic 
Dysfunction in High-Fat Diet Fed 
Rodents
Paul M. Ryan1,2,3, Elaine Patterson1,3, Robert M. Kent1,2, Helena Stack4, Paula M. O’Connor1,2, 
Kiera Murphy1, Veronica L. Peterson5, Rupasri Mandal6, David S. Wishart6,7,8, Timothy G. 
Dinan3,9, John F. Cryan  3,5, Randy J. Seeley10, Catherine Stanton1,3 & R. Paul Ross1,3
The gut hormone glucagon-like peptide (GLP)-1 and its analogues represent a new generation of anti-
diabetic drugs, which have also demonstrated propensity to modulate host lipid metabolism. Despite 
this, drugs of this nature are currently limited to intramuscular administration routes due to intestinal 
degradation. The aim of this study was to design a recombinant microbial delivery vector for a GLP-1 
analogue and assess the efficacy of the therapeutic in improving host glucose, lipid and cholesterol 
metabolism in diet induced obese rodents. Diet-induced obese animals received either Lactobacillus 
paracasei NFBC 338 transformed to express a long-acting analogue of GLP-1 or the isogenic control 
microbe which solely harbored the pNZ44 plasmid. Short-term GLP-1 microbe intervention in rats 
reduced serum low-density lipoprotein cholesterol, triglycerides and triglyceride-rich lipoprotein 
cholesterol substantially. Conversely, extended GLP-1 microbe intervention improved glucose-
dependent insulin secretion, glucose metabolism and cholesterol metabolism, compared to the high-
fat control group. Interestingly, the microbe significantly attenuated the adiposity associated with 
the model and altered the serum lipidome, independently of GLP-1 secretion. These data indicate that 
recombinant incretin-secreting microbes may offer a novel and safe means of managing cholesterol 
metabolism and diet induced dyslipidaemia, as well as insulin sensitivity in metabolic dysfunction.
GLP-1 is a short conserved mammalian peptide produced by enteroendocrine L-cells that can stimulate insulin 
production to lower postprandial glucose levels in patients with type-2 diabetes (T2D)1,2. While GLP-1 has been 
known to interact with an array of additional systems – including the brain3, liver4 and stomach5 – its role in lipid 
metabolism and cardiovascular health has only recently emerged6. However, the incretin is rapidly cleaved and 
rendered inactive by circulating dipeptidyl peptidase (DPP)-4. As such, numerous drugs have explored extending 
the effects of GLP-1, either by synthetic stimulation of the GLP-1 receptor (GLP-1R) by DPP-4-resistant ana-
logues (e.g. exendatide and lirglutitide) or direct inhibition of DPP-4 activity (e.g. gliptins).
GLP-1, GLP-1R agonists and DPP-4 inhibitors have all shown varying abilities to suppress enteric cell chylo-
micron production, made phenotypically evident by a reduction in circulating triglycerides and apolipoprotein 
B-48 (apoB-48)7–9. Chylomicrons are triglycerides-rich lipoprotein particles, which are formed in the endoplas-
mic reticulum of enterocytes and transport triglycerides to adipose, skeletal and cardiac tissues. These structures 
have now been identified as contributors to arterial cholesterol accumulation and consequently, are at the core of 
dyslipidaemia-induced atherosclerosis in obese and insulin resistant individuals10. While it is acknowledged that 
GLP-1 impacts upon host satiety and weight, factors which could credibly alter lipid metabolism, these studies 
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indicate a direct effect on enteric GLP-1R as the central mechanism. Moreover, GLP-1R signaling has also been 
shown to correct endothelial dysfunction11, while also reducing blood pressure by activating atrial natriuretic 
peptide12.
The propensity of certain members of the gut microbiota to prevent or progress cardiovascular disease (CVD), 
as well as other aspects of metabolic health, is becoming increasingly apparent13. Intestinal bacteria constantly 
deliver metabolites, such as short chain fatty acids, which regulate host metabolism14. In recent years, studies 
have harnessed the potential of engineering bacteria as live cell factories for the production of desirable ‘designer’ 
bioactive molecules or drugs in vivo, with the aim of managing human health issues from allergies to obesity15–18. 
These treatments have been termed synthetic signalling therapeutics19. A recent study from Duan et al. investi-
gating the use of such a therapeutic in a streptozotocin model of type-1 diabetes (T1D) demonstrated the ability 
of a probiotic transformed to express the full-length, inactive form of GLP-1 (1–37) to restore one third of the host 
insulin production20. The strain was found to interact with small intestinal crypt epithelial cells through the sig-
nalling molecule, transforming them into insulin secreting β-like cells. Further to this, the Wallenberg Laboratory 
for Cardiovascular & Metabolic Research recently performed a similar study with Lactococcus lactis secreting 
the same full length peptide in diet-induced obese mice21. Indeed, this study also reported encouraging results; 
increasing pancreatic insulin secretion and glucose clearance in a model of hyperglycaemia, thereby improving 
glucose tolerance.
The aim of the present study was to assess the potential of a long-lasting GLP-1 analogue (termed KGLP-1) 
secreting microbe to improve metabolic function in diet-induced obese rodents. More specifically, it was hypoth-
esised that the microbe may attenuate insulin resistance, and the gross atherogenic dyslipidaemia associated 
with obesity and T2D. This study builds on previous research demonstrating the practicality of microbes as 
incretin-signalling vectors in models of metabolic dysfunction.
Results
GLP-1-Secreting Microbe Elicits Insulin Secretion in Murine β-Cells. In vitro assays revealed that 
synthetic KGLP-1 compared favourably with Sigma Standard GLP-17–37 in terms of insulinotropic activity. 
Moreover, when compared with Sigma Standard GLP-17–37 and synthetic KGLP-1 at levels of 50 µM the micro-
bial-generated DPP-4-resistant GLP-1 induced similar levels of insulin secretion (Fig. 1C), which were higher 
than typical reported post-prandial levels of GLP-1 in circulation in vivo22. In addition, PNZ supernatant demon-
strated no significant insulinotropic effects, when compared to the control media.
Experiment I – Short-Term Diet-Induced Obese Rat Model. Short-Term GLP-1-Secreting Microbe 
Intervention Improves Diet-Induced Dyslipidaemia. While fasted serum lipid profiling revealed no signifi-
cant alteration in total cholesterol, LDL-C was found to be significantly reduced in the group receiving GLP-
1-secreting Lb. paracasei NCIMB 338 (GLP1; 19% reduction, p < 0.05; Fig. 2G), while treatment with GLP1 also 
resulted in 20% lower serum triglycerides levels compared with the isogenic control (PNZ; p < 0.05; Fig. 2D). 
Mean serum apoB-48 level in PNZ group was 164 µg.ml−1, while GLP1 rats demonstrated a mean of 122 µg.ml−1 
(Fig. 2F); trending towards significance (p = 0.06). Finally, calculations applied to fasting lipid and cholesterol 
data uncovered a significant reduction in triglyceride-rich lipoprotein cholesterol (TRL-C) in the GLP1 group 
when compared to PNZ (p < 0.05; Fig. 2I), while TRL-mediated atherogenic dyslipidaemia (TLR-AD) index was 
unchanged (Fig. 2J). Despite these alterations in lipid metabolism, no significant alteration was observed in rat 
weight gain (Fig. 2B). Although GLP1-treated rats displayed a corrected serum lipid and cholesterol profile, oral 
glucose tolerance test (OGTT) results suggest that they failed to regulate their blood glucose more effectively 
than the control rats (Fig. 2C). There were no significant differences between the two groups at any of the selected 
time points or in area under the curve (AUC), and there was no significant difference in IR index between the 
two groups (Supplementary Table S2). Finally, compositional sequencing of the caecum microbiome revealed no 
significant alterations (Supplementary Table S3 and Figure S1), indicating that any metabolic effect was a direct 
result of the GLP1 intervention on the host, and not microbiome-mediated.
Experiment II – Extended Diet-Induced Obese Mouse Model. Extended Lactobacillus paracasei 
NFBC 338 Intervention Attenuates Adiposity Independently of GLP-1-Expression. Over the 12 week intervention 
period (Fig. 3A), body weights of the high-fat diet fed groups remained similar (Fig. 3B). However, both microbial 
interventions (PNZ and GLP1) accumulated significantly less mesenteric adipose tissue (MAT; p < 0.001) and 
significantly reduced epididymal adipose tissue (EAT) when compared to the HFC (p < 0.05; Fig. 3C). Despite 
such promising effects, GLP1 treated mice were consistently found to be statistically similar to PNZ mice in each 
of these metrics, suggesting that the expression of GLP-1 was not the functional component for reduction of 
adiposity. Rather, this is likely the result of Lb. paracasei NFBC 388 or alternative metabolites derived from the 
microbe.
Extended GLP-1-Secreting Microbe Intervention Improves Glucose Metabolism and Insulin Sensitivity. Following 
13 weeks of high-fat diet prefeeding (Fig. 3A), glucose and insulin tolerance tests revealed that HF-fed mice were 
sufficiently intolerant when compared to LF-fed animals to commence interventions (Fig. 4A–D). Following 
an additional 12 weeks feeding in conjunction with intervention, mice were again assessed for their glucose 
(Fig. 4E,F) and insulin tolerance (Fig. 4G,H). Prior to the glucose challenge, solely GLP1 (p < 0.05) and LFC 
(p < 0.0001) mice displayed a reduced fasting blood glucose concentration when compared to the HFC (Fig. 4E). 
The results of the intraperitoneal glucose tolerance test (IPGTT) assay demonstrate that extended intervention 
with GLP1 significantly attenuates the disruption of glucose metabolism observed in HF-fed mice, with reduced 
blood glucose at 0 min (p < 0.05), 45 min (p < 0.01), 90 min (p < 0.05) and 120 min (p < 0.05; Fig. 4E), while PNZ 
treatment had no such effect. Further to this, GLP1 mouse AUC glycaemia was found to be significantly lower 
www.nature.com/scientificreports/
3SCIENTIFIC RePORtS | 7: 13523  | DOI:10.1038/s41598-017-14010-x
than the HFC (p < 0.05), while PNZ was not (Fig. 4F). However, neither GLP1 glycaemia nor glycaemia AUC 
were found to be significantly lower at any time point, when compared to the PNZ group.
Bloods were also drawn to assess insulin concentration at 0 min (fasting) and 15 min of the IPGTT. 
Interestingly, while all high-fat fed groups were statistically similar prior to IP, at 15 min GLP1 mice displayed a 
significantly elevated insulin level when compared to the HFC (p < 0.01; Fig. 4G), which resulted in an elevated 
insulinaemia AUC (p < 0.05; Fig. 4H). This result is particularly validating for the therapy, as GLP-1-based inter-
ventions exert insulinotropic effects only in the presence of glucose. This in turn corroborates the in vitro data 
demonstrating the insulinotropic effects of the secreted KGLP-1 peptide. Curiously, both GLP1 (p < 0.0001) and 
PNZ intervention (p < 0.0001) reduced blood glucose levels in the first two time points of the insulin tolerance 
test (ITT; Fig. 4I). In addition, both groups again appeared to significantly reduce ITT AUC when compared to 
the HFC (p < 0.01). However, the great deal of variation observed in the ITT may detract from the reliability of 
this metric.
Extended GLP-1-Secreting Microbe Intervention Improves Cholesterol Metabolism. Assessment of serum prior 
to mixed meal gavage indicates that, of the two treatment groups, solely the GLP1 group demonstrated reduced 
fasting cholesterol (p < 0.05; Fig. 4K,L). To determine how capable the mice were of managing their post-prandial 
cholesterol, we delivered the complete liquid meal orally. Following the challenge, the HFC group cholesterol lev-
els spiked high and remained at the same concentration (~270 mg/dL) over the 18 h monitoring period. Although 
the two other HF-fed groups reacted in a similar fashion over the first 4 h, they both displayed a greatly reduced 
serum cholesterol concentration at 18 h post-feed (p < 0.001). Importantly, although PNZ-treated mice displayed 
a reduced AUC (p < 0.05), GLP1 cholesterolemia AUC was found to be further reduced when compared to that 
of PNZ (p < 0.01).
Figure 1. Microbial-Produced GLP-1 Displays Insulinotropic Activity Comparable to Synthetic Peptide.  
(A) pNZ44-KGLP-1 plasmid construct with KGLP-1 amino acid sequence; (B) Overlaid MALDI-TOF spectra 
of PNZ (red) and GLP1 (blue) spent cell-free growth medium HPLC fractions, with KGLP-1 peak (3512 Da) 
indicated by arrow. Inset graph displays KGLP-1 production during culture of PNZ (red) and GLP1 (blue) 
microbes, as assessed by ELISA of cell-free media; (C) Insulin production by Rinm5F-Beta cells treated with 
Lactobacillus paracasei NFBC 338 PNZ or GLP1 filtrate preparations, or pure KGLP-1 and GLP-1 peptides 
(50uM). Data was analysed by one-way ANOVA, significant differences are represented by ****(p < 0.0001) 
and plots depict replicates with mean and SEM.
www.nature.com/scientificreports/
4SCIENTIFIC RePORtS | 7: 13523  | DOI:10.1038/s41598-017-14010-x
Extended Lactobacillus paracasei NFBC 338 Intervention Alters Host Amino Acid, Biogenic Amine and Phosphotidy 
lcholine Metabolism. Targeted analysis of the fasted mouse serum metabolome unveiled a number of key metabolic 
alterations as a result of microbial intervention. Figure 5A depicts a sample × metabolite heatmap which displays sam-
ples in a dendogramatic alignment. Interestingly, we see that the HFC serum metabolomes appear to cluster away from 
those of both PNZ and GLP1 groups, both of which remain intertwined. This microbial-modulated shift in the metab-
olome is further portrayed in the amino acid and biogenic amine principle coordinate analysis (PCoA) plot (Fig. 5B), 
as both PNZ and GLP1 cluster clearly away from the HFC; but again the two microbial groups remain intertwined. 
Exaggeration of this clustering can be seen in guided sparse partial least square-discriminate analysis (sPLS-DA) plot 
loadings (Supplementary Figure S3A and B). The specific fluctuations observed include increased levels of ornith-
ine (q < 0.05), and decreased levels of amino acids glutamine and histamine (q < 0.05), and several biogenic amines 
(ac-ornithine [q < 0.001], α-AAA [q < 0.05], carnitine [q < 0.05], met-SO [q < 0.05], spermidine [q < 0.05] and taurine 
[q < 0.01]) in PNZ/GLP1 when compared to the HFC (Fig. 5C). In addition, a plethora of long-chain diacyl PC (PC aa) 
and acyl-alkyl PC (PC ae) reductions were also observed in the microbial intervention groups when compared to the 
HFC, and this shifted the serum molecular signature considerably (Fig. 5D). However, the secretion of GLP-1 had no 
additional effect on the metabolic signature.
Discussion
The management of metabolic syndrome and related conditions must be of top priority in global health agenda. 
An estimated 382 million people worldwide are currently living with diabetes23, meaning that the development 
of affordable and effective means of managing the symptoms of the disease, particularly in the early stages, is 
becoming increasingly urgent. GLP-1-based therapies have shown their efficacy in improving glucose metabolism 
Figure 2. Short-Term GLP-1-Secreting Lactobacillus paracasei Intervention Modulates Lipid but Not Glucose 
Metabolism. Experiment I: (A) Schematic of study timeline, with high-fat diet represented by yellow bar and 
intervention by broken grey bar. (B) Weight gain of PNZ (red) and GLP1 (light blue) rats over treatment period. 
(C) Oral Glucose Tolerance Test: blood glucose of PNZ (red) and GLP1 (light blue) treatment groups before 
and after glucose challenge. (D) Fasting serum triglycerides, (E) total cholesterol, (F) apoB-48, (G) LDL-C and 
(H) HDL-C of PNZ (red) and GLP1 (light blue) treatment groups at cull for experiment I. (I) Triglyceride-
rich lipoprotein cholesterol (TLR-C) and (J) triglyceride-rich lipoprotein-mediated atherogenic dyslipidaemia 
(TLR-AD) index were calculated from the data above. Figures represent the mean with SEM or max and min 
bars (n = 9). Significant differences are represented by *(p < 0.05).
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in T2D3. However, due to the degradability of short peptides24, these treatments are often limited to intramus-
cular or intraperitoneal injection. The use of bacteria as synthetic signalling therapeutics for the management 
or prevention of certain disease states has garnered attention, but has shown limited success until recently. One 
such therapeutic which has demonstrated considerable potential, and is now in phase 2a clinical trials, is an 
interleukin-10 secreting L. lactis, which has previously been shown to protect against colitis in a preclinical model 
of the disease25.
As introduced previously, the works of both Duan et al.20 and Arora et al.21 act as a proof of concept for 
incretin-secreting bacterial therapies, demonstrating that recombinant microbes may have applications in mod-
ulation of metabolic dysfunction. Further to this, the work described herein details specifically the action of an 
active GLP-1 analogue, and also extrapolates the utility of such therapies in the management of the atherogenic 
dyslipidaemia associated with obesity and diabetes. In addition, we should address the specific compositions and 
bioactivities of the secreted peptides. Indeed, the full length precursor form of GLP-1 has shown the potential 
to reach circulation and activate pancreatic β-cells; however, its half-life is still very short due to DPP-4 activity, 
perhaps necessitating relatively regular dosing. Conversely, assuming similar peptide expression and absorption 
rates between the microbes and hosts in each of these studies, the recombinant Lb. paracasei in the present study 
may in fact be more suitable as a therapeutic considering it secretes a DPP-4-resistant analogue of active GLP-1, 
thereby demonstrating greatly increased half-life.
While commercial GLP-1-based therapies have been shown to have a corrective effect on atherogenic dyslip-
idaemia and hypertriglyceridemia8,26, until recently the mechanisms involved in this effect were poorly under-
stood. However, it now appears that GLP-1-based therapies can have broader cardioprotective effects through two 
main pathways. Firstly, when GLP-1R located in the heart are stimulated, this causes the release of atrial natriu-
retic peptide, a hormone which acts in lowering blood pressure through smooth muscle relaxation12. Secondly, 
and perhaps most significantly with respect to our data, GLP-1 and GLP-1R agonists are known to act on entero-
cyte GLP-1R, resulting in a repression of chylomicron formation3,27. This in turn reduces circulating levels of tri-
glycerides, apoB-48 and to some degree cholesterol9,28, which has important implications for CVD development. 
Furthermore, a reduction in pancreatic triglycerides, such as is seen following bariatric surgery, is associated with 
profound beneficial implications for T2D host metabolic health, in terms of insulin secretory abilities29.
In experiment I, fasting rat serum LDL-C and triglycerides levels in rats receiving the GLP-1-secreting probi-
otic were significantly reduced by ~20%, while apoB-48 levels were found to be approaching a significant reduc-
tion (p = 0.06). As has previously been alluded to, triglycerides and apoB-48 represent primary components of 
intestinally derived chylomicrons. These results indicate that the GLP-1-secreting probiotic has the potential 
Figure 3. Lactobacillus paracasei Attenuates Mouse Adiposity Independently of GLP-1-Expression. 
Experiment II: (A) Mouse trial design and procedures detailed above, with high-fat diet represented by 
yellow bar and intervention by broken grey bar. (B) Delta change in body weights over the pre-feeding (white 
background) and intervention (red background) periods for HFC (dark red; n = 13), PNZ (light red; n = 14), 
GLP1 (light blue; n = 14) and LFC (dark blue; n = 14). Tall dark red boxes represent metabolic test weeks 
(IPGTT/ITT and mixed meal gavage, respectively). (C) Epididymal (EAT), subcutaneous (SAT) and mesenteric 
adipose tissue (MAT), and liver tissue weights are also depicted. Data was analysed by one-way ANOVA with 
Bonferroni correction, significant differences are represented by *(p < 0.05), **(p < 0.01), ***(p < 0.001), 
****(p < 0.0001), where the asterisks are coloured according to the group with which a significant difference 
was recorded. Plots depict replicates with mean and SEM.
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to reduce the abundance of these potentially atherogenic fragments, perhaps through the previously identified 
enterocyte GLP-1R pathway. In order to assess the CVD risk in the rats following the three week intervention, the 
log(TG)/HDL-C calculation for TRL-AD was applied to the data. In addition, TRL-C calculations were applied 
to evaluate the levels of intestine-derived chylomicron and hepatic-derived very-low density lipoprotein. While 
TRL-C showed significant improvement as a result of GLP1 treatment, TRL-AD was found to be statistically 
similar between the two groups. It is likely that the three week intervention period was too short to demonstrate 
a more complete correctional effect on host atherogenic dyslipidaemia state. Entirely promising is the comple-
mentary reduction in fasting cholesterol and overall an improvement in postprandial cholesterol metabolism was 
observed following GLP1 intervention in a separate model organism, under the modified conditions detailed in 
experiment II. It is important to note that humans spend the majority of their day in postprandial-state27 and, as a 
result, fed-state cholesterol and lipid profiles have been determined to be more indicative of CVD risk30,31.
Despite there being no significant effect on glucose metabolism in the rat study (experiment I), the GLP1 inter-
vention did have a substantial effect on this metabolic aspect in the diet-induced obese (DIO) mice in experiment II. 
This may have been a result of chronic rather than acute intervention, and establishment of the diet-induced 
phenotype prior to intervention. The substantial increase in the diet fat proportion (60% in experiment II versus 
40% in experiment I) also likely contributed to the increased effect size in this test. In addition, IPGTT have been 
shown to produce different results when compared to OGTT12. However, it is clear from the GTT and ITT results 
in experiment II that Lb. paracasei intervention had some degree of effect on glucose homeostasis, independently 
of GLP-1 expression. Therefore, it is plausible that a similar effect may indeed have been observed in experiment I, 
had a HFC group been included. The same effect can be seen in attenuation of mouse adiposity observed in 
Figure 4. GLP-1-Expressing Lactobacillus paracasei Improves Glucose & Cholesterol Metabolism While 
Promoting Glucose-Dependant Insulin Secretion. Experiment II: HFC (n = 7) and LFC (n = 7) animals were 
assessed for 1 g/kg glucose (IPGTT) and 0.75 IU/kg insulin (ITT) tolerance at week 12 of feeding, prior to 
commencement of interventions. (A) IPGTT; (B) IPGTT area under the curve (AUC); (C) ITT; (D) ITT AUC. 
At week 22 of feeding/week 10 of intervention HFC (n = 7), PNZ (n = 14), GLP1 (n = 13) and LFC (n = 7) 
animals were again assessed for glucose and insulin tolerance. (E) IPGTT glucose levels; (F) IPGTT glucose 
AUC; (G) IPGTT insulin levels (T0 and T15); (H) IPGTT insulin AUC; (I) ITT glucose levels; (J) ITT glucose 
AUC. Animals were assessed for lipid and cholesterol metabolism by oral gavage with a complete meal (K,L) 
Ensure Plus, Abbott Nutrition). Data was analysed by one-way ANOVA with Bonferroni correction. Significant 
differences are represented by *(p < 0.05), **(p < 0.01), ***(p < 0.001), ****(p < 0.0001), where the asterisks 
are coloured according to the group which they represent. Plots depict replicates with mean and SEM.
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experiment II, all of which suggest that the naïve bacteria must secrete additional unidentified factors which con-
tribute somewhat to host metabolic function.
Finally, investigation into the serum metabolome revealed a range of alterations in amino acids and lipids, 
with previously reported implications for host metabolism. PC, a family of phospholipids which contain a choline 
headgroup, are key structural constituents of apoB, and are therefore integral components of chylomicron, LDL-C 
and VLDL-C particles. In turn, it has been previously demonstrated that impaired hepatic PC synthesis leads to 
reduced circulating levels of these particles, brought about by depleted synthesis and elevated uptake. Therefore, 
it is likely that the extensive reduction in PC is, at least in part, responsible for the shifts in both cholesterol and 
triglyceride metabolism observed for microbial-intervention groups. Interestingly, these shifts in lipid metabo-
lism were previously found to be coupled with reduced atherogenesis. While metabolomics research is still, in 
many ways, in catologuing stages and the full implications of such metabolites for host metabolic function are not 
entirely clear, links are being identified between certain PC and metabolic dysfunction. In line with this, a number 
of long-chain PC have been shown to be elevated in clinical studies of T2D, correlating negatively with insulin 
secretion and sensitivity32. While the manner in which microbes interact with host lipid metabolism have been 
explored previously in preclinical models33,34, the exact molecular underpinnings remain incompletely elucidated.
Conclusion
This study is the first to assess the application of a recombineered microbe as a synthetic signalling therapeutic 
for the delivery of an active and long-lasting analogue of GLP-1 to the host intestine. The expression system used 
utilized the leader and export machinery of the bacteriocin pediocin to enable efficient production and export 
of GLP-1. The aim of this intervention was to improve glucose and lipid-load handling in DIO rodent models of 
metabolic dysfunction. The results indicate that three weeks of GLP1 intervention was sufficient to reduce fasted 
rat serum triglycerides and LDL-C levels substantially. In addition, GLP1 intervention significantly improved 
overall cholesterol metabolism and reduced fasting hypercholesterolemia in DIO mice, when compared to the 
non-incretin-secreting isogenic control. However, extended intervention with the GLP-1-expressing microbe 
was necessary to improve host glucose metabolism. It is likely that the lipid metabolism effects observed were 
mediated by intestinal GLP-1R activation, while correction of glucose homeostasis may be the result of pancre-
atic beta-cell GLP-1R activation. Finally, these results indicate that GLP-1-secretion was in fact not necessary for 
attenuation of adiposity and alteration of the serum amino acid and lipid metabolome by Lb. paracasei NFBC 
338 over a 12-week intervention period. These data indicate that recombinant, hormone-secreting microbes may 
offer a novel therapeutic avenue for the management of host metabolic dysfunction. In conclusion, we build upon 
Figure 5. Lactobacillus paracasei Modulates Host Amino Acid, Biogenic Amine & Phosphotidylcholine 
Metabolism Independently of GLP-1-Expression. (A) Experiment II: Serum metabolome heatmap, with 
dendogram clustering according to sample likeness. (B) Principle Coordinate Analysis (PCoA) plot displays 
HFC (green), PNZ (.blue) and GLP1 (red) samples. (C,D) Quantitative data is displayed for the metabolites 
which were significantly altered by GLP1 or PNZ; this includes amino acids and biogenic amines, as well as 
diacyl-phosphatidylcholine (PC aa) and acyl-alkyl-phosphatidylcholine (PC ae). *(q < 0.05), **(q < 0.01), 
***(q < 0.001), ****(q < 0.0001) represent significant differences between both PNZ/GLP1 and HFC. Plots 
depict individual replicates (n = 10) with mean and SEM.
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previous proof-of-concept work, which has proven the utility of GLP-1-secreting microbes in preclinical models 
of T1D and T2D, by demonstrating an effect on lipid metabolism and atherogenic lipid profile, while also profil-
ing the effects of microbial therapy on the host metabolome.
Materials and Methods
Recombinant Microbe. The nucleotide sequence for KGLP-1 was synthesised by overlap extension PCR 
(OE-PCR) using primers 1, 2, 3 and 4 outlined in Supplementary Table S1. DNA was extracted from Pediococcus 
acidilacti DPC 5492 and the pediocin leader (pedlead) sequence was amplified using primers 5 and 6. A splic-
ing OE-PCR reaction using primers 2 and 5 was used to combine the KGLP-1 sequence (Fig. 1A) and pediocin 
leader. PCR reactions were carried out at 60 °C using KOD polymerase (Merck Millipore). Mature pediocin was 
generated using primers 6 and 7. The pedB, (specifies immunity), pedC and pedD genes (membrane bound pro-
teins required for peptide secretion)35 were amplified from P. acidlilacti DPC 5492 DNA using primers 7 and 8. 
The restriction sites Pst1 and Kpn1 were incorporated into the sequence to allow incorporation into the plasmid 
pNZ44 via ligation reaction36. Restriction polymerases and T4 DNA ligase were purchased from New England 
Biolabs (240 County Rd., Ipswich, MA, USA).
Plasmid constructs were transformed into competent E. coli which was spread plated on LB agar containing 
10 µg/ml chloramphenicol and incubated overnight. Successful transformants were treated with a Plasmid Mini 
kit (Qiagen). Electrocompetent Lb. paracasei NFBC 338 cells were prepared using 3.5X SMEB (1 M sucrose, 
3.5 mM MgCL2). Plasmids were electroporated into Lb. paracasei NFBC 338 which was plated as described ear-
lier with the addition of 10 µg/ml chloramphenicol. The relevant DNA fragments were verified by restriction 
endonucleases and gel electrophoresis. Correct DNA sequences were validated by DNA sequencing (Beckman 
Coulter Genomics, Essex CM22 6TA, United Kingdom). Lb. paracasei NFBC 338 is an established probiotic 
strain which has demonstrated amenability for recombineering and is resistant to the stresses of gastrointestinal 
transit37. The recombinant KGLP-1-secreting variant was designated as GLP1 and the isogenic control for this 
construct was Lb. paracasei NFBC 338 solely containing the pNZ44 plasmid, transformed in the same manner 
and was subsequently designated PNZ.
All bacteria were routinely cultured on de Mann Rogosa Sharp (MRS; Difco) anaerobically at 37 °C with the 
addition of 10 µg ml−1 chloramphenicol (MRSCM10; Sigma Aldrich, Ireland) to select for recombinant bacteria. 
Bacteria were firstly cultured from −80 °C stock on solid agar media and all subsequent subcultures were in broth.
KGLP-1 Peptide Detection. Peptide expression and secretion was confirmed by matrix-assisted laser des-
orption ionization time of flight mass spectrometry (MALDI-TOF MS; Fig. 1B) of a high performance liquid 
chromatography fraction of the cell-free spent MRS broth. In brief, spent MRS culture broth was centrifuged 
at 10,000 x g for 10 min, before being passed through a 0.22 μm filter. Samples were then passed through a 3 ml, 
200 mg, C18 SPE pre-equilibrated with methanol and water. The column was washed with 3 ml 30% ethanol and 
then 2 ml 70% isopropan-2-ol, 0.1% TFA (IPA). The IPA was removed from the sample and it was applied to an 
analytical Proteo Jupiter RP-HPLC column running a 27–55% gradient over 35 minutes where buffer B is 90% 
acetonitrile 0.1% TFA. Previously a 25–55% gradient with buffer B as 100% acetonitrile 0.1% TFA was used had 
to reduce the acetonitrile concentration of buffer B to extend the life of the degasser on the HPLC, consequently 
KGLP will elute slightly later than previously. Fractions were collected and fractions 31–34 from each run were 
checked for the presence of the 3512 Da KGLP-1 using MALDI TOF mass spectrometry.
In addition, the kinetics of microbial KGLP-1 secretion were analysed in cell-free spent MRS broth during 
culture at several points over an 18 hour period by total GLP-1 MSD kit (Meso Scale Discovery; Fig. 1B inset), as 
per the manufacturer’s instructions.
In Vitro Insulinotropic Activity Assay. RINm5F Insulinoma cells (Rattus norvegicus) (ATCC-CRL-11605) 
(LGC Standards, Queens Road, Teddington, Middlesex, TW11 0LY, England) were cultured in RPMI-1640 (LGC 
Standards) medium containing 10% (v/v) foetal bovine serum, and 1% (v/v) Penicillin-Streptomycin solution 
(Sigma Aldrich: Cat. No. P0781). All cells were maintained in 75 cm2 sterile tissue culture flasks (Corning Inc, 
NY, USA) at 37 °C in an atmosphere of 5% CO2. Cells were passaged when the confluency of the flasks was 
approximately 90%. For insulinotrophic studies, cells were treated with trypsin and seeded into six well tissue 
culture plates (Sarstedt, Sinnottstown Lane, Drinagh, Co. Wexford, Ireland) at a density of 1 × 105 cells/well.
Insulinotrophic properties of Lb. paracasei NFBC 388 GLP1 generated peptides were investigated using a 
method previously described38 with minor alterations. Briefly 2 ml of RINm5F cells were cultured as described. 
Cell monolayers were washed using KREBS-Ringer bicarbonate buffer (Sigma Aldrich) and starved for 40 min at 
a basal glucose level via addition of 1 ml of KREBS buffer containing 1.1 mM glucose (Sigma Aldrich). Buffer was 
removed and the cells were stimulated with prepared (0.22 nm filtered) filtrate from Lb. paracasei NFBC 338 PNZ 
and GLP-1. Each sample was incubated with glucose at 2.2 mM, 4.4 mM or 8.8 mM for 20 min. Sigma GLP-1 and 
synthetic KGLP-1 were also assayed at 50 µmol, nmol and pmol for comparison. Following incubation samples 
were collected and treated with protease and phosphatase inhibitor (10 µl/ml) (Fisher Scientific UK Ltd, Bishop 
Meadow Road, Loughborough, UK.; Cat. No. PN78443) before being applied to a MSD insulin plate (Cat. No. 
K152BZC-1). Insulin production was measured according to manufacturer’s instructions using a MSD Sector 
2400.
Treatment Preparation. The engineered probiotic and control bacteria were cultured as previously 
described until stationary phase and centrifuged (16,900 x g for 15 min, at 4 °C; SLA-3000 rotor, Sorvall RC 
B5-Plus). The cell pellet was washed twice with phosphate buffered saline (PBS; Sigma Aldrich), resuspended at 
~2 × 1010 CFU.ml−1 in sterile 15% trehalose (Sigma Aldrich) and 1 ml aliquots were dispensed into 2 ml lyoph-
ilisation vials. The vials were lyophilised on a 24 h program (freeze temperature −40 °C, additional freeze 1 min, 
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condenser set point −60, vacuum set point 600 mTorr; VirTis AdVantage Wizard 2.0) and stored at 4 °C until use. 
Bacteria were resuspended in distilled water each day in order to deliver 109 CFU/d to each animal. Gastric transit 
of the strains was assessed each week by culturing serial dilutions of fresh faecal samples on MRSCM10 plates, as 
described previously.
Animal Experiments. All animals were acclimatised for 1 week in the housing facility prior to trial com-
mencement. Animals were group-housed at 21 °C in a 12-h light–dark cycle (light cycle 07:00–19:00). Two ani-
mal experiments were conducted in this study. Experiment I was a diet-induced obesity (DIO) rat model carried 
out in the Metabolic Disease Institute of University of Cincinnati, approved by and performed according to the 
guidelines of the Institutional Animal Care and Use Committee of the University of Cincinnati. Experiment II was 
a DIO mouse model performed in the APC Microbiome Institute of University College Cork and experimental 
procedures were carried out as per the protocols approved by the University College Cork Ethics Committee, with 
a license acquired through the Health Products Regulatory Authority.
Experiment I. As an initial proof of concept study, 20 Long-Evans rats were maintained on a high-fat butter 
diet (4.54 kcal/g; 41% fat; Research Diets, NJ, USA) ad libitum for 6 weeks prior to treatment. The animals were 
individually caged and kept on a 12 h light/dark cycle. Following the initial 6 weeks, body composition (NMR; 
EchoMedical Systems, Houston, TX) and weights were assessed, allowing the animals to be distributed into either 
the treatment or control groups, counterbalancing for these parameters. Following allocation, the rats remained 
on the high-fat diet while concurrently receiving either the incretin-secreting Lb. paracasei (GLP1; n = 10) or the 
isogenic control strain which solely expressed the empty pNZ44 plasmid vector (PNZ; n = 10) for an additional 
17 d prior to the oral glucose tolerance test (OGTT). Animals were culled following 21 d of intervention.
Experiment II. Three week old C57BL/6 mice were acquired from Envigo UK and maintained in a 12 h light/
dark cycle and on a high-fat diet (Open Source Diets [D12492 – 60% kcal from fat; Research Diets Inc.]) ad 
libitum for 25 weeks in total and for the final 12 weeks exposed to 109 CFU/mouse.d−1 of GLP1 (n = 14), PNZ 
(n = 14) or no intervention (HFC; n = 14). An additional group of animals were maintained on a low-fat control 
diet (LFC; n = 14; Open Source Diets [D15072701 – 10% kcal from fat and equal parts corn starch and sucrose; 
Research Diets Inc.]) concurrently, acting as a negative control for development of obesity and insulin resistance. 
Animal weight gain and food intake were continuously assessed. In addition, intraperitoneal glucose and insulin 
tolerance tests were performed at weeks 12 and 24, while a mixed-meal gavage test was also performed at the end 
of the intervention to explore lipid and cholesterol metabolism.
Metabolic Assessment. Oral Glucose Tolerance Test. Rats from experiment I were fasted overnight prior 
to OGTT. Baseline blood glucose was recorded in duplicate at T0 by tail bleed (Accu-Chek glucometers and 
strips; Roche, UK) and 2 g/kg 25% (w/v) dextrose was delivered intragastrically by oral gavage. Blood glucose 
was subsequently recorded in the same manner at 15, 30, 45, 60 and 120 min post glucose loading. In addition, 
β-cell function was assessed by insulin resistance index following quantification of insulin (Rat Insulin ELISA, 
Mercodia) in serum bleeds at 0 and 15 min. The equation used to calculate insulin resistance (IR) index was as 
follows39:
= ∗ ∗ −IR index Glucose area under the curve AUC Insulin AUC( ) 10 (1)4
Intraperitoneal Glucose Tolerance Test. Mice from experiment II were fasted from the start of light-cycle for 
6 hours prior to IPGTT. Baseline blood glucose was recorded in duplicate at T0 by tail bleed (Accu-Chek glu-
cometers and strips; Roche) and 1 g D-glucose per kg of bodyweight was delivered by intraperitoneal injection. 
Blood glucose was subsequently recorded in the same manner at 15, 45, 90 and 120 min post glucose loading. 
In addition, β-cell function was assessed by IR index following quantification of insulin (Mouse Insulin ELISA, 
Mercodia) in plasma bleeds 0 and 15 min. The equation used to calculate IR index was as above.
Insulin Tolerance Test. ITT were performed on fasted mice from experiment II in the same manner as the 
IPGTT, with intraperitoneal injection of 0.75 IU insulin per kg of bodyweight. Blood glucose was monitored by 
the same method at T0 and the same timepoints post insulin challenge.
Mixed Meal Gavage. Mice from experiment II were fasted from the start of light-cycle for 6 hours prior to mixed 
meal gavage. Each mouse received 200 µl Ensure Plus (Abbott Nutrition, Ireland) by gastric oral gavage, and 
tail bleeds were performed at T0, 2, 4 and 18 h post gavage. The plasma was then analysed for cholesterol levels 
(EnzyChrom colorimetric assay; Cambridge Biosciences, UK).
Serum Lipid and ApoB-48. Total serum cholesterol (TC) levels were determined in duplicate as per the 
manufacturer’s instructions using the EnzyChrom colorimetric assay (ECCH-100, BioAssay Systems, Hayward, 
CA, USA). Similarly, serum high-density lipoprotein-cholesterol (HDL-C), low-density lipoprotein cholesterol 
(LDL-C) and triglycerides were determined by their respective LabAssay assays (Wako Diagnostics, Germany). 
ApoB-48 in rat serum was quantified by ELISA (MyBioSource, SD, USA). Finally, the equation validated by 
Hermans et al.40 was applied to calculate TRL-C, and is as follows:
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− = − . ∗ − . ∗
+ . ∗ . ∗ − − + .
− . ∗ . − −
TRL C TC TC triglycerides
TC HDL C
HDL C
[(0 0106 0 0036
0 017 [0 65 ( ) 6 3]
0 27) 38 6] (2)
TLR-AD index was assessed by the following formula41:
− = −TRL AD log TG HDL C[ ]/ (3)
Compositional Microbiome Sequencing. At the end of Experiment I, caecum content bacterial DNA 
was assessed to ensure that the effects observed were not mediated by fluctuations in the microbiome compo-
sition. Roughly 200 mg of caecal content was weighed out and added to a 2 ml tube containing sterile silicon 
beads. Extraction buffer was added and the tubes were vortexed for 3 min each. Following this, microbial DNA 
was extracted using the QIAamp DNA Stool Mini Kit protocol (Qiagen, UK). The primer pair 5′-TCGT CGGC 
AGCG TCAG ATGT GTAT AAGA GACA GCCT ACGG GNGG CWGC AG-3′ and 5′-GTCT CGTG GGCT 
CGGA GATG TGTA TAAG AGAC AGGA CTAC HVGG GTAT CTAA TCC-3′ were used to amplify the V3-V4 
regions of the 16 S genes found in the isolated microbial DNA, as per the preparation manual for the Illumina 
MiSeq platform. Illumina Nextera kit (Illumina Nextera XT, Illumina) was used to tag samples with unique bar-
codes prior to quantification with the Qubit High Sensitivity DNA kit (Life Technologies, Ireland), pooling and 
sequencing.
FLASH (FLASH: fast length adjustment of short reads to improve genome assemblies) was applied for the 
assembly of resulting 300 bp paired-end reads. Additional sequence read processing, which included quality filter-
ing based on a quality score of > 25 and removal of mismatched barcodes and sequences below length thresholds, 
was performed within QIIME (version 1.8.0). USEARCH (version 7, 64-bit) was utilised for denoising, chimera 
detection and clustering into operational taxonomic units (OTUs) (97% identity). OTU sequences were subse-
quently aligned using PyNAST (PyNAST: python nearest alignment space termination), after which taxonomy 
was assigned at 97% similarity against the SILVA SSURef database release 111. Alpha diversity estimates and beta 
diversity were calculated using QIIME and PCoA plots were created in EMPeror (version 0.9.3-dev; Emperor) 
and used to visualise differences in beta diversity based on UniFrac distances.
Serum Metabolome Profiling. Serum collected from mice at cull of Experiment II was analyzed using 
the Biocrates AbsoluteIDQ p180 Kit (BIOCRATES Life Sciences AG, Austria). Following initial extraction and 
derivatization steps, a range of specific amino acids, biogenic amines, acylcarnitines, lysophosphotidylcholines, 
phosphotidylcholines (PC), sphingomyelins and hexoses present in the samples were detected and quantified on 
an ABI 4000 Q-Trap mass spectrometer (MDS Sciex) run in conjunction with a reverse-phase HPLC-column.
Primary Splenocyte Stimulation. Spleens were removed immediately subsequent cull at Experiment II 
and maintained on chilled RPMI media prior to mechanical disruption and filtration through 70 μm Nylon Cell 
Strainers to isolate a single cell suspension. Red blood cells were removed following the procedure detailed in 
the Mouse Erythrocyte Lysis solution (Sigma Aldrich). Isolated cells were washed twice, counted by trypan blue 
exclusion and resuspended in DMEM supplemented with 10% foetal bovine serum (FBS) and 1% penicillin/
streptomycin antibiotics to a concentration of 2 × 106 cells/ml. Wells were stimulated with 1 μg/ml lipopolysac-
charide42 (Sigma Aldrich) and incubated at 37 °C in 5% CO2 for 48 hours, while duplicate wells were also left 
unstimulated as controls. Plates were then centrifuged at 300 g and supernatants aspirated and stored at for anal-
ysis. Supernatant concentrations of the cytokines interleukin (IL)-10, IL-6 and tumour necrosis factor (TNF)-α 
were assessed using the mouse V-PLEX Plus Proinflammatory Panel 1 Kit (K15048G-1; Meso Scale Discovery, 
Ireland).
Serum ELISA and Enzymatic Assays. Trunk serum was analysed by ELISA for levels of insulin (Mercodia 
Mouse Insulin ELISA; Cat No. 10-1247-01; Uppsala, Sweden), leptin (Crystal Chem Inc.; Cat. No. 90030; IL 
60515, USA), C-peptide (Crystal Chem Inc.; Cat. No. 90050; IL 60515, USA), adiponectin (Crystal Chem Inc.; 
Cat. No. 80569; IL 60515, USA) and glucagon (Mercodia Glucagon ELISA – 10 μl; Cat No. 10-1281-01; Uppsala, 
Sweden). Trunk serum was analysed by enzymatic assay for glucose (Crystal Chem Inc.; Cat. No. 81692; IL 60515, 
USA) and glycated haemoglobin (HbA1c, Crystal Chem Inc.; Cat. No. 80310; IL 60515, USA) according to the 
protocols described by the manufacturers.
Statistical Analysis. All datasets, apart from microbiome and metabolome data, were analysed in Prism 
5 (GraphPad Software Inc.) by one-way analysis of variance (ANOVA) or unpaired, two-way Student’s t-test 
when stated, both with Bonferroni correction for multiple testing. Metabolomic data was log normalised prior to 
ANOVA and multivariate analyses in the MetaboAnalyst metabolomics analysis suite43. Sparse partial least square 
discriminant analysis (sPLS-DA) was also performed on metabolomic data44. Finally, non-normal sequenc-
ing data were analysed by Kuskal-Wallis, followed by 2-tailed Mann-Whitney U pairwise comparisons, with 
Bonferroni correction for multiple testing. For metabolomic and microbiome data, a false discovery rate (FDR) q 
value less than 0.05 was considered statistically significant.
Data Availability. Sequencing and metabolomics data is to be made freely available in a public database and 
all additional in vitro and animal data is available upon request.
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